BIOCRYST PHARMACEUTICALS, INC. (BCRX) Return on equity 2016–2019
BIOCRYST PHARMACEUTICALS, INC. (BCRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-284.7%FY2019 · since FY2016: -3494.6% → -284.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2019 | -284.7% | -79.0 pp |
| FY2018 | -205.7% | -127.1 pp |
| FY2017 | -78.5% | +3416.0 pp |
| FY2016 | -3494.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More BCRX financial trends
BCRX RevenueBCRX Net incomeBCRX Net marginBCRX Gross profitBCRX Gross marginBCRX Operating incomeBCRX Operating marginBCRX Operating cash flowBCRX Free cash flowBCRX Capital expendituresBCRX Stock buybacksBCRX Dividends paidBCRX Total assetsBCRX Total liabilitiesBCRX Shareholders’ equityBCRX overview →